By Andrew Silver SHANGHAI (Reuters) -Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next year, its CEO said on Tuesday, the ...

Semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. | Drug ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone. Ozempic for blood sugar control and Wegovy for weight loss both use different ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

Plastic surgery trends show growing acceptance of aesthetic procedures as self-care, with over 28.5 million minimally ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...